DeepCyte is a biotechnology company that offers predictive products for toxicology using single-cell metabolomics technology.
DeepCyte has raised $1.5M in total funding. The most recent round was Seed. The last funding was announced in April 2026.
DeepCyte's investors include Carl Evertsz.
DeepCyte is headquartered in Wilmington, United States.
DeepCyte is a biotechnology company that offers predictive products for toxicology using single-cell metabolomics technology.
DeepCyte is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"DeepCyte — Funding & Investors." VCBacked, April 9, 2026, https://www.vcbacked.co/company/deepcyte. Accessed July 31, 2026.
VCBacked. (2026). DeepCyte — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/deepcyte
{{cite web |title=DeepCyte — Funding & Investors |url=https://www.vcbacked.co/company/deepcyte |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated